|Articles|November 1, 2001

New Directions in the Treatment and Prevention of Deep Vein Thrombosis
Volume 7
Issue 17 Suppl

Interview

Author(s)An interview with Alex C. Spyropoulos, MD

Download PDF: Interview

Articles in this issue

almost 25 years ago

Article

Participating Faculty

almost 25 years ago

Article

Introduction

almost 25 years ago

Article

Treatment of Deep Vein Thrombosis Using Low-Molecular-Weight Heparins

almost 25 years ago

Article

Prophylaxis Strategies for Patients with Acute Venous Thromboembolism

almost 25 years ago

Article

Economic Issues in the Treatment and Prevention of Deep Vein Thrombosis From a Managed Care Perspective

almost 25 years ago

Article

The Use of Pharmacoeconomics in Formulary Development: Can This Improve the Way Deep Vein Thrombosis is Treated?

almost 25 years ago

Article

Continuing Medical Education Quiz

almost 25 years ago

Article

Literature Review

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Predicting GLP-1 Discontinuation From Pharmacy Claims

ByAayush Sisodia, MSHI, BDS

Published: August 6th 2026 | Updated: August 31st 2026

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

ByThomas W. Martens, MD,Bimal V. Patel, PharmD, MS,Sharon M. Wang, PharmD, MS,Laurel H. Messer, PhD, MPH, RN, CDCES, BC-ADM,Jordan E. Pinsker, MD,Daniel C. Malone, PhD, RPh,Miranda R. Polin, MS, BS,Diana I. Brixner, PhD, RPh,Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES,Osagie Ebekozien, MD, MPH

July 23rd 2026

Geographical Access to Preferred Pharmacies in Medicare Part D

ByPinka Chatterji, PhD,Yiran Han, PhD,Chun-Yu Ho, PhD

July 22nd 2026

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

Interview

Articles in this issue

Related Content

Predicting GLP-1 Discontinuation From Pharmacy Claims

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

Geographical Access to Preferred Pharmacies in Medicare Part D

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Trending on AJMC

Daraxonrasib Clears FDA as First RAS-Targeted Pancreatic Cancer Drug

As GLP-1 Costs Climb, Medicare Part D Plans Face a Reckoning

New York Experts Push for Coordinated Obesity Care Teams

Grocery Assistance Benefit Linked to Fewer Diabetes Complications

Early Secukinumab Sustains Psoriasis Clearance a Year After Stopping